Skip to main content
. Author manuscript; available in PMC: 2024 Jan 24.
Published in final edited form as: Aliment Pharmacol Ther. 2023 Nov 15;59(1):80–88. doi: 10.1111/apt.17783

TABLE 1.

Baseline characteristics.

Variables MEFIB-negative, N = 193 (65%) MEFIB+ and MRI-PDFF ≥5%, N = 79 (27%) MEFIB+ and MRI-PDFF <5%, N = 24 (8%) p-value
Age, years (SD) 52.8 (13.5) 65.1 (8.4) 66.9 (7.3) <0.0001
Male, n (%) 86 (44.6) 34 (43.0) 11 (45.8) 0.9613
Diabetes, n (%) 85 (44.0) 57 (72.2) 19 (82.6) <0.0001
Hypertension, n (%) 62 (32.1) 36 (45.6) 16 (66.7) 0.0015
Dyslipidaemia, n (%) 106 (55.5) 45 (57.0) 9 (37.5) 0.2160
BMI (kg/m2), mean (SD) 30.1 (6.0) 28.4 (5.1) 28.9 (4.1) 0.0740
Race, n (%)
 White 72 (37.3) 19 (24.1) 12 (50.0) 0.1285
 Hispanic 25 (13.0) 10 (12.7) 4 (16.7)
 Asian 91 (47.2) 49 (62.0) 8 (33.3)
 Others 5 (2.6) 1 (1.3) 0 (0)
AST (U/L), median (IQR) 29.0 (18.5) 47.0 (36.0) 34.5 (30.5) <0.0001
ALT (U/L), median (IQR) 41.0 (36.5) 42.0 (41.0) 29.0 (25.0) 0.1324
Total bilirubin (mg/dL), median (IQR) 0.40 (0.32) 0.60 (0.51) 0.92 (0.93) <0.0001
Albumin (g/dL), median (IQR) 4.5 (0.4) 4.3 (0.5) 4.2 (0.5) <0.0001
Creatinine (mg/dL), median (IQR) 0.77 (0.16) 0.80 (0.26) 0.69 (0.38) 0.0251
Triglycerides (mg/dL), median (IQR) 169.0 (111.0) 163.0 (92.0) 142.0 (88.5) 0.1046
HDL (mg/dL), median (IQR) 48.0 (11.5) 47.0 (13.0) 45.4 (18.0) 0.2395
LDL (mg/dL), median (IQR) 129.5 (40.0) 120.0 (35.0) 101.0 (45.0) 0.0003
HbA1c (%), median (IQR) 6.1 (0.9) 6.5 (1.7) 6.5 (1.4) 0.0111
Platelet count (109/L), median (IQR) 249.0 (81.5) 150.0 (87.0) 123.5 (59.0) <0.0001
PT INR, median (IQR) 1.00 (0.06) 1.04 (0.11) 1.13 (0.23) <0.0001
FIB-4, median (IQR) 1.08 (0.75) 3.06 (2.02) 4.08 (2.28) <0.0001
MRE (kPa), mean (SD) 2.90 (1.09) 5.37 (1.51) 5.92 (1.64) <0.0001
MRI-PDFF, mean (SD) 13.15 (8.09) 12.07 (6.19) 3.18 (0.87) <0.0001

Abbreviations: AST, aspartate aminotransferase; ALT, alanine aminotransferase; BMI, body mass index; HbA1c, Haemoglobin A1c; HDL, high-density lipoprotein; IQR, interquartile range; LDL, low-density lipoprotein; FIB-4, fibrosis index based on the 4 factor; MEFIB, MRI combined with FIB-4; MRE, magnetic resonance elastography; MRI-PDFF, magnetic resonance imaging derived proton density fat fraction; PT INR, prothrombin time international normalised ratio; SD, standard deviation.